<DOC>
	<DOCNO>NCT00976989</DOCNO>
	<brief_summary>This 3 arm study assess tolerability , safety efficacy 3 neoadjuvant treatment regimens participant locally advance , inflammatory early stage human epidermal growth factor receptor 2 ( HER2 ) -positive breast cancer . Before surgery , participant randomize receive either A ) 6 cycle pertuzumab plus trastuzumab ( Herceptin ) , 5-fluorouracil/epirubicin/cyclophosphamide ( FEC ) cycle 1-3 docetaxel cycle 4-6 , B ) FEC cycle 1-3 follow pertuzumab plus trastuzumab docetaxel cycle 4-6 , C ) 6 cycle pertuzumab plus trastuzumab docetaxel carboplatin . Pertuzumab administer load dose 840 mg intravenously ( iv ) , 420 mg iv 3-weekly , trastuzumab load dose 8 mg/kg iv , 6 mg/kg iv 3-weekly , docetaxel 75 mg/m^2 iv , increase 100 mg/m^2 iv 3-weekly , FEC carboplatin iv 3-weekly standard dos . Following surgery participant receive trastuzumab 6 mg/kg iv 3-weekly total 1 year , well adequate chemo- , radio- hormone therapy . Anticipated time study treatment 4-12 month , target sample size 200-300 .</brief_summary>
	<brief_title>A Study Pertuzumab Combination With Herceptin Chemotherapy Participants With HER2-Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>female participant , age &gt; /=18 year advance , inflammatory early stage unilateral invasive breast cancer HER2positive breast cancer baseline leave ventricular ejection fraction ( LVEF ) &gt; /=55 % metastatic disease ( Stage IV ) bilateral breast cancer previous anticancer therapy radiotherapy malignancy malignancy , except carcinoma situ cervix , basal cell carcinoma clinically relevant cardiovascular disease current chronic treatment corticosteroid &gt; 10mg methylprednisolone equivalent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>